<div id="readability-page-1">This is a paid sponsorship on behalf of MindBio Therapeutics Corp.  Most AI headlines today are dominated by chatbots, productivity tools, and incremental software upgrades.  But some of the more interesting AI developments are happening far away from consumer apps — in healthcare, safety, and risk detection — where human voice is being treated as a measurable biological signal .  That’s where MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) comes in.  MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) operates at the intersection of artificial intelligence, voice analysis, and digital health — an emerging field where subtle changes in how people speak can signal measurable shifts in cognition and physiology. Over the past five years, MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) has built and trained its platform on more than 50 million voice data points , identifying distinct voice-based biomarkers associated with impairment and physiological stress.  Using short voice samples alone, MindBio Therapeutics’ (CSE: MBIO) (OTCQB: MBQIF) AI applies machine learning models to generate real-time risk signals — without hardware, wearables, or invasive testing.  This is not a theoretical concept.  The technology is already live.  Alcohol impairment remains a massive, largely unsolved global problem. It cuts across road safety, workplace compliance, healthcare and addiction treatment, insurance, transportation, and liability management. Existing tools are hardware-dependent, location-bound, and often reactive rather than predictive.  MindBio Therapeutics’ (CSE: MBIO) (OTCQB: MBQIF) approach is fundamentally different. By using voice as the input, intoxication detection can be instant, remote, and software-driven , potentially deployable anywhere a microphone exists. If impairment can be detected without physical devices, it changes how and where monitoring can occur.  That shift alone has implications well beyond breathalyzers.  Importantly, MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is not operating from a pitch deck. The company launched its consumer web and mobile application in 2025 , has a functional AI platform trained on real-world voice data , and is actively developing enterprise solutions focused on drug and alcohol impairment detection and voice analytics in regulated environments.  This is deployable technology aimed at real-world use cases.  From a technology perspective, voice analysis checks several boxes that investors increasingly care about: non-invasive data collection, software-only deployment, massive scalability, and compounding data advantages as usage grows. As the system ingests more voice data, the models improve, reinforcing a potential data flywheel.  The bigger question is whether intoxication detection is just the starting point.  Across healthcare research, voice is increasingly being explored as a digital biomarker — a signal that may help screen for disease earlier and more cheaply than traditional methods. Changes in tone, rhythm, amplitude, and breathing patterns are already being studied in neurological and neurodegenerative disorders like Parkinson’s and Alzheimer’s disease, mental health conditions such as depression and anxiety, respiratory diseases including asthma, COPD, and COVID-19, as well as voice disorders, certain cancers, and even cardiovascular and metabolic conditions.  If voice can function as a scalable health signal, the long-term implications extend into continuous, remote, low-cost screening across some of the largest healthcare markets globally.  Leadership matters in early-stage stories, and MindBio Therapeutics’ (CSE: MBIO) (OTCQB: MBQIF) board brings notable healthcare execution experience. Chairman Gavin Upiter previously founded Generic Health , which was sold to Lupin Pharmaceuticals (NSE: LUPIN) . His background also includes executive roles at Bristol Myers Squibb (NYSE: BMY) , serving as Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX) , leadership at Slade Health , Australia’s largest hospital pharmacy chain, and founding Directo , Australia’s first online B2B pharmaceutical marketplace.  This is not first-time leadership experimenting with AI — it is experienced healthcare operators applying AI to a new category.  From a market-structure standpoint, MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) also stands out. The company has a notably tight share structure , with approximately 4.8 million shares outstanding . In small-cap markets, limited float often increases sensitivity to news flow, commercial validation, and shifts in investor narrative. Management retains meaningful ownership, reinforcing alignment with shareholders.  Why does this matter now?  MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) sits at the intersection of several trends investors are watching closely: AI moving beyond consumer novelty into real-world risk detection, healthcare adopting software-first and non-invasive tools, and voice analysis emerging as a legitimate data category. The market may still view the company through a biotech lens, but the underlying technology increasingly resembles AI infrastructure applied to safety and healthcare .  The re-rating question ultimately comes down to execution and scalability.  But the category itself is no longer theoretical.  MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is already live, operating in real-world conditions, and targeting multiple large markets simultaneously.  For investors focused on asymmetric opportunities, early-category formation, and technology-driven narrative shifts, this is a name that is beginning to show up on more screens.  Learn more at: https://mindbiotherapeutics.com/ .  This article is a paid advertisement on behalf of MindBio Therapeutics Corp. and should not be seen as investment advice.  Senergy Communications Capital Inc. (“Senergy”) DBA AI Capital News, has been compensated CAD $150,000 by MindBio Therapeutics Corp. to provide marketing and investor awareness services. Senergy also holds zero common shares of MindBio Therapeutics Corp. but may buy or sell these securities without notice at any time.  Statements and opinions expressed are those of the author and not necessarily those of Senergy, its directors, officers, or employees. The author is wholly responsible for the validity of the statements. Senergy has not independently verified all such information and does not guarantee its accuracy or completeness. The information provided is for informational purposes only and should not be construed as a recommendation to buy or sell any security.  This article does not constitute investment advice. All investments carry risk, and readers should consult their own financial advisors before making any investment decisions. Any action taken by readers as a result of this information is at their own risk. This article is not a solicitation for investment, nor does Senergy provide general or specific investment advice.  Forward-Looking Information  This document may contain “forward-looking statements” within the meaning of applicable Canadian securities laws. Such statements reflect management’s expectations regarding future growth, business plans, and opportunities of MindBio Therapeutics Corp. Forward-looking statements are based on numerous assumptions and are subject to known and unknown risks and uncertainties, many of which are beyond the control of MindBio Therapeutics Corp. Actual results may differ materially. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, MindBio Therapeutics Corp. undertakes no obligation to update or revise any forward-looking statements. Please refer to SEDAR+ for all filings and updated information on MindBio Therapeutics Corp.  Investing involves significant risks, including the possible loss of the entire investment. Past performance is not necessarily indicative of future results. Readers should conduct their own due diligence, carefully consider their risk tolerance, and seek professional advice before investing.  Senergy is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on this article or on www.senergy.capital and www.aicapitalnews.com constitutes advice or a recommendation.</div>

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

<p>MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) 正在利用人工智能和语音分析来检测健康信号，特别是针对酒精影响的检测。他们的技术使用语音样本生成实时风险信号，无需硬件支持。该公司已推出消费者应用程序，并正在开发用于药物和酒精检测的企业解决方案。MindBio 专注于非侵入性、可扩展的健康监测，正在探索将语音作为各种健康状况的数字生物标志。领导团队拥有丰富的医疗保健经验，公司在紧凑的股权结构下运营，增强了其市场敏感性</p>

这家小型股 AI 公司正在押注人类声音可以作为实时健康信号